MRC Molecular Haematology Unit, MRC Weatherall Institute of Molecular Medicine, Radcliffe Department of Medicine, University of Oxford, Oxford OX3 9DS, UK.
Curr Opin Genet Dev. 2024 Jun;86:102191. doi: 10.1016/j.gde.2024.102191. Epub 2024 Apr 4.
To make a multicellular organism, genes need to be transcribed at the right developmental stages and in the right tissues. DNA sequences termed 'enhancers' are crucial to achieve this. Despite concerted efforts, the exact mechanisms of enhancer activity remain elusive. Mixed lineage leukemia (MLL or KMT2A) rearrangements (MLLr), commonly observed in cases of acute lymphoblastic leukemia (ALL) and acute myeloid leukemia, produce novel in-frame fusion proteins. Recent work has shown that the MLL-AF4 fusion protein drives aberrant enhancer activity at key oncogenes in ALL, dependent on the continued presence of MLL-AF4 complex components. As well as providing some general insights into enhancer function, these observations may also provide an explanation for transcriptional heterogeneity observed in MLLr patients.
为了生成一个多细胞生物体,基因需要在正确的发育阶段和正确的组织中转录。被称为“增强子”的 DNA 序列对实现这一点至关重要。尽管付出了协同努力,但增强子活性的确切机制仍然难以捉摸。混合谱系白血病(MLL 或 KMT2A)重排(MLLr)在急性淋巴细胞白血病(ALL)和急性髓系白血病中很常见,产生新的框内融合蛋白。最近的工作表明,MLL-AF4 融合蛋白在 ALL 中的关键癌基因上驱动异常的增强子活性,这依赖于 MLL-AF4 复合物成分的持续存在。这些观察结果不仅为增强子功能提供了一些一般性的见解,也可能为 MLLr 患者中观察到的转录异质性提供了解释。